Psychedelics Company Profiles

Click on a company name below to view key financials, press releases and interviews.

ATAI Life Sciences

Beckley Psytech

Better Plant Sciences (PLNT)

CaaMTech

Champignon Brands Inc. (SHRM)

COMPASS Pathways (CMPS)

Cybin Inc.

Eleusis

Entheon Biomedical

Field Trip (FTRP)

Havn Life (HAVN)

Hollister Biosciences (HOLL)

MagicMed Industries

MindMed (MMED)

Mydecine Innovations Group (MYCO)

Numinus (NUMI)

Revive Therapeutics Ltd. (RVV)

Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major Depressive Disorder StudyMay 27, 2025
As Gilgamesh Pharmaceuticals is set to share positive results from its Phase 2a study of GM-2505 (aka bretisilocin, a serotonergic psychedelic) in major depressive disorder later today at ASCP, we speak with the company’s Chief Strategy and Development Officer Jorge Quiroz and Chief Operating Officer Yoni Falkson to dig a little deeper into the study, its results, and the company’s plans for the candidate.
Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics CzarMay 24, 2025
Matt Zorn made his name suing federal agencies over cannabis and psychedelics policy. Now, he’s inside the system as Deputy General Counsel at HHS, with what appears to be a mandate over psychedelics reform. Here, we recount Zorn's path from 'thorn in the side' of the federal government to insider, what we might expect from him in his new role, and how insiders are reacting to the news.
Pα+ Psychedelic Bulletin #198: New Data Offers Look at Spravato’s Long-Term Use, Highlights Psychedelic Opportunity; MAHA Report Slams Psychiatric Meds; Momentum Builds for BeckleyMay 23, 2025
New Data Offers Look at Spravato’s Long-Term Use, Highlights Opportunity for Psychedelics • MAHA Report Slams Psychiatric Drug Use Among America’s Youth, Trump Era Drug Policy Priorities Raise Questions for Psychedelics • Beckley Psytech’s Small Study Supports Adjunctive Use of 5-MeO-DMT with SSRIs in TRD • and more...
Psychedelics in Japan: Dr. Hiroyuki Uchida on Studies, Stigma, and the Road AheadMay 21, 2025
As global interest in psychedelic therapies grows, Japan is beginning to chart its own path, grounded in cultural nuance, regulatory caution, and scientific rigour. In this interview, Dr. Hiroyuki Uchida of Keio University discusses his journey into psychedelic research, the challenges of launching Japan’s first psilocybin trials, and the steps being taken to ensure a safe, culturally appropriate psychedelic future.
FDA’s Makary Hints at Faster Reviews for Psychedelic TherapiesMay 19, 2025
In a brief interview on Friday, FDA Commissioner Marty Makary publicly addressed psychedelic therapies for the first time in his new role, floating the potential for expedited reviews. While he emphasised urgency, he stopped short of outlining any concrete policy changes. Here, we cover the interview and provide our analysis.

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.